The Cambridge IBS Study

Effects of probiotics on the caecal and faecal microbiota of Irritable Bowel Syndrome patients receiving antibiotics: a pilot study

SUMMARY

This double-blind, placebo-controlled study examines the role of probiotic administration in the prevention of C. difficile-associated diarrhoea (CDAD) in elderly patients receiving antibiotic therapy.​
Results showed that Lab4 probiotics reduced the incidence of Clostridium difficile diarrhoea in these patients.​
46% of patients supplemented with Lab4 probiotics were positive for Clostridium difficile toxin compared to 78% of patients in the placebo group

Aim

This study assessed the effect of Lab4 probiotic supplementation on the composition of the microbiota in IBS sufferers receiving antibiotic therapy.

Method

Results

Caecal Biopsy and Caecal Lumen

  • In Group 1, significant increases in the detection of yeasts and Candida albicans were recorded at day 14.
  • In Group 1, decreases were recorded in the detection of bifidobacteria and lactobacilli at day 14.
  • In Group 2, detection of yeasts was reduced at day 14 compared with Group 1.
  • Faeces

    • Group 2  – detection of yeasts was reduced at day 14 compared with Group 1.
    • Group 1 – the percentage of IBS sufferers harbouring yeasts at day 28 (14 days after terminating antibiotic treatment) was higher than at day 0.
    • Group 2 – yeasts were not detected in the faecal samples at day 28.

    Conclusion

    The supplementation of IBS sufferers with Lab4 probiotics prior to and alongside antibiotics may provide protection against overgrowth by yeasts.
    Scroll to Top